Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference

Rhea-AI Summary

Picard Medical (NYSE: PMI) highlighted new clinical and preclinical data at THT 2026, presenting three sessions March 2–4 that cover updated registry analyses of the SynCardia Total Artificial Heart and early in vitro/in vivo results for the fully implantable Emperor system.

Presentations emphasize outcomes beyond survival — stabilization, organ recovery, functional improvement, and preserved transplant eligibility — and report that the Emperor preserves SynCardia’s physiologic performance while aiming to remove transdermal drivelines and improve mobility.

Positive

• FDA and Health Canada approvals for SynCardia Total Artificial Heart
• Updated registry analyses show outcomes beyond survival
• Preclinical Emperor data preserve proven physiologic performance

Negative

• Emperor results are early preclinical, leaving clinical benefit unconfirmed
• Renal and neurological outcomes remain major determinants of long-term success

News Market Reaction – PMI

%

6 alerts

% News Effect

-5.5% Trough in 29 hr 47 min

$80M Market Cap

0.1x Rel. Volume

On the day this news was published, PMI declined NaN%, reflecting a moderate negative market reaction. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Number of presentations: 3 presentations Conference dates: March 2–4, 2026 First session time: 4:15 PM EST +2 more

5 metrics

Number of presentations 3 presentations Scientific and educational talks at THT 2026

Conference dates March 2–4, 2026 Technology and Heart Failure Therapeutics (THT) 2026

First session time 4:15 PM EST Scientific abstract presentation on March 2

Second session time 3:28 PM EST Educational lecture on March 3

Third session time 8:50 AM EST Clinical outcomes presentation on March 4

Market Reality Check

Price: $0.9601 Vol: Volume 214,207 is below t...

low vol

$0.9601 Last Close

Volume Volume 214,207 is below the 20-day average of 2,003,139, suggesting limited pre-news activity. low

Technical Shares at $1.08 are trading below the $2.78 200-day moving average, after a -92.11% slide vs the 52-week high.

Peers on Argus

PMI fell 6.09% while peers were mixed: CTKB up 5.66%, KIDS down 5.10%, LAB down ...

1 Down

PMI fell 6.09% while peers were mixed: CTKB up 5.66%, KIDS down 5.10%, LAB down 5.31%, AVMR and ZIMV flat. The pattern points to stock-specific pressure rather than a uniform medical devices move.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Conference training day	Positive	-0.9%	Hands-on SynCardia training at THT 2026 for multidisciplinary teams.
Feb 23	Surgical training event	Positive	-7.1%	Invitation-only SynCardia surgical training for leading heart transplant centers.
Feb 12	Clinical milestone case	Positive	-1.2%	Successful bridge-to-transplant case at UCSF using SynCardia Total Artificial Heart.
Feb 10	Conference presentation	Positive	-4.2%	Emperor Total Artificial Heart data presentation at European MCS summit.
Jan 29	Investor webinar	Positive	-2.8%	Webinar on Emperor fully implantable total artificial heart and preclinical data.

Pattern Detected

Recent positive clinical and promotional news around SynCardia and the Emperor system has repeatedly coincided with short-term share price declines.

Recent Company History

Over the past weeks, PMI has highlighted SynCardia Total Artificial Heart training initiatives, clinical milestones, and multiple presentations on its fully implantable Emperor system. Events included a DeviceTalks webinar, European and U.S. conference presentations, and a successful bridge-to-transplant case at UCSF. Despite the constructive clinical and education focus, the stock posted negative 24h reactions after each of the last 5 news items, suggesting a pattern of selling into positive operational updates.

Market Pulse Summary

This announcement underscores Picard Medical’s emphasis on clinical data, physician education, and n...

Analysis

This announcement underscores Picard Medical’s emphasis on clinical data, physician education, and next-generation technology for the SynCardia Total Artificial Heart and Emperor systems. Multiple THT 2026 presentations cover preclinical performance, future therapy directions, and real-world outcomes beyond survival. In the broader context of recent training events and regulatory filings, investors may track ongoing data readouts, adoption at leading centers, and how financing structures and authorized share increases interact with the company’s clinical and commercial execution.

Key Terms

total artificial heart, mechanical circulatory support, preclinical, in vitro, +4 more

8 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

mechanical circulatory support medical

"reinforcing Picard Medical’s leadership in advanced mechanical circulatory support."

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

preclinical medical

"early laboratory and preclinical data demonstrating that the Emperor system preserves"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

in vitro medical

"The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s"

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

in vivo medical

"The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

registry analyses medical

"This presentation will highlight updated registry analyses showing that outcomes"

Registry analyses are studies that examine information collected in organized databases that track patients, treatments or device use over time to see how products perform in the real world. For investors, these analyses act like long-term customer reports: they reveal actual safety, effectiveness, usage patterns and market uptake beyond clinical trials, which can change expectations for sales, regulatory risk and future competitive advantage.

renal medical

"Renal and neurological outcomes remain major determinants of long-term success."

Renal means relating to the kidneys, the body’s filters that remove waste and balance fluids and salts. Investors care because renal conditions and treatments drive demand for drugs, devices, diagnostics and hospital care; changes in effectiveness, safety, approval or cost of renal therapies can affect company revenues, regulatory risk and health-care spending, much like a clog in a key pipeline affects an entire system.

neurological medical

"Renal and neurological outcomes remain major determinants of long-term success."

Relating to the nervous system — the brain, spinal cord and the network of nerves that control thought, movement and bodily functions. For investors, the word signals that a drug, device or test targets complex circuitry whose successes or failures can sharply affect clinical trial outcomes, regulatory approval and long-term sales potential, much like fixing or breaking the main electrical wiring in a building impacts all downstream systems.

AI-generated analysis. Not financial advice.

New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system

TUCSON, Ariz., March 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs, will deliver three scientific and educational presentations at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston from March 2^nd to March 4^th 2026. Dr. Simon’s presentations will focus on both the current SynCardia Total Artificial Heart (STAH) and the Company’s next-generation fully implantable Emperor system, reinforcing Picard Medical’s leadership in advanced mechanical circulatory support.

Dr. Andre Simon commented, “Total artificial heart therapy continues to evolve through both clinical experience and technological innovation. Our goal is not only survival, but meaningful recovery, improved quality of life, and preservation of transplant opportunity. Picard Medical’s participation at THT reflects the Company’s ongoing commitment to scientific exchange, physician education, and innovation in next generation artificial heart technology.”

More information on Dr. Simon’s three presentations is below:

Format: Scientific Abstract Presentation
Date and Time: Monday, March 2; 4:15 PM EST; HF Focus Station 2 | Ensemble C-D | Level 2
Title: “The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart”

Dr. Simon will present early laboratory and preclinical data demonstrating that the Emperor system preserves the proven physiologic performance of the SynCardia Total Artificial Heart. The fully implantable architecture is designed to eliminate transdermal pneumatic drivelines and enable improved mobility, quality of life, and long-term patient independence.

Format: Educational Lecture
Date and time: Tuesday, March 3; 3:28 PM EST; Ensemble E-F | Level 2
Title: “The Total Artificial Heart of the Future: My Wish List”

In this invited session, Dr. Simon will discuss the future evolution of total artificial heart therapy, including clinical priorities such as earlier intervention, organ recovery, improved patient selection, and the transition from bridge to transplant toward durable long-term support.

Format: Clinical Outcomes Presentation

Date and Time: Wednesday, March 4; 8:50 AM EST; Ensemble C-D | Level 2
Title: “Beyond Survival: Defining Success After Total Artificial Heart Implantation”

This presentation will highlight updated registry analyses showing that outcomes with the SynCardia Total Artificial Heart extend beyond survival to include stabilization, organ recovery, functional improvement, and preservation of transplant eligibility. Key findings include sustained clinical success in critically ill patients, improved outcomes in patients implanted earlier in their disease trajectory, strong recovery potential even in patients initially not eligible for transplant, and significant improvements in quality of life after early postoperative recovery. Renal and neurological outcomes remain major determinants of long-term success.

About THT 2026
Technology and Heart Failure Therapeutics (THT) 2026 is an international conference focused on advancing innovation in heart failure through emerging device, technology, and combination therapies. Sponsored by the Cardiovascular Research Foundation, THT brings together leading clinicians, researchers, and industry partners to share the latest clinical data, discuss regulatory and commercial pathways, and explore future trends shaping the management of advanced heart failure. The multidisciplinary program features cutting-edge scientific sessions, case-based discussions, and hands-on training designed to foster collaboration and improve patient outcomes. For more information, visit https://www.thtmeeting.com/about-tht.

About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

What did Picard Medical (PMI) announce at THT 2026 on March 2–4?

Picard Medical presented three THT 2026 sessions on the SynCardia Total Artificial Heart and Emperor system. According to Picard Medical, sessions covered registry outcomes beyond survival, early Emperor in vitro/in vivo data, and future clinical priorities.

What do the updated registry analyses for SynCardia TAH presented by PMI show?

The registry analyses report outcomes beyond survival, including stabilization and organ recovery. According to Picard Medical, findings note improved outcomes with earlier implantation and quality-of-life gains after early postoperative recovery.

What is the Emperor system and what did PMI report about its data?

The Emperor is a next-generation fully implantable total artificial heart designed to remove transdermal drivelines. According to Picard Medical, early in vitro and in vivo data show it preserves SynCardia’s physiologic performance.

How might the SynCardia presentations affect patients and clinicians, according to PMI?

Presentations stress meaningful recovery, improved quality of life, and preserving transplant opportunity. According to Picard Medical, emphasis includes earlier intervention, organ recovery, and better patient selection for durable support.

What limitations did Picard Medical note about long-term success after TAH implantation?

Picard Medical highlighted that renal and neurological outcomes remain critical determinants of long-term success. According to Picard Medical, these factors strongly influence recovery and transplant eligibility after implantation.